It has been about a month since the last earnings report for Phibro Animal Health (PAHC) . Shares have added about 2.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Phibro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Phibro Q4 Earnings and Revenues Beat, Oper ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Abbott (ABT) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our ...

Phibro Animal Health Corporation's (PAHC) sustained growth in the Animal Health business is backed by robust sales of vaccines and Medicated Feed Additives ("MFAs"). The company's focus on advancing vaccine technologies, along with the new vaccine production unit, instills optimism. Strong sales growth outside the United States seems encouraging. Yet, adverse macroeconomic impacts are a concern for Phibro's operations. In the past year, this Zacks Rank #2 (Buy) stock has rallied 71.5% compared with the indu ...

Phibro Animal Health's (PAHC) diversified product portfolio and wide presence in key growth areas bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving PAHC's Growth Phibro's key animal health products, including Medicated Feed Additives (MFAs) and nutritional specialty products, enhance animal nutrition. The company's leading product franchise, Stafac/V-Max/Eskalin, is approved in more than 30 countries for use in poultry and swine. Similarly, the company's ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock cha ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estimate r ...

Zacks Premium and Style Scores - Zacks Premium offers daily updates of Zacks Rank and Zacks Industry Rank, full access to Zacks 1 Rank List, Equity Research reports, and Premium stock screens to help investors make informed decisions [1] - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, assigning ratings from A to F, with A being the best [2][3] - The Style Scores are divided into four categories: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] - Zacks Rank, a proprietary stock-rating model, uses earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks averaging a +25.41% annual return since 1988 [6][7] - Combining Zacks Rank 1 or 2 with Style Scores of A or B increases the likelihood of stock success [8][9] Phibro Animal Health (PAHC) - Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company, offering nearly 770 product lines in over 80 countries to approximately 4,000 customers [10] - PAHC holds a Zacks Rank of 2 (Buy) with a VGM Score of A and a Momentum Style Score of B, with shares up 18.4% over the past four weeks [11] - For fiscal 2025, two analysts revised their earnings estimates upwards in the last 60 days, increasing the Zacks Consensus Estimate by $0.04 to $1.46 per share, with an average earnings surprise of 4.1% [11] - PAHC is recommended for investors due to its strong Zacks Rank and top-tier Momentum and VGM Style Scores [12]

Have you evaluated the performance of Phibro Animal Health's (PAHC) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this maker of animal health products and nutritional supplements, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth. In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal fa ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2024 Earnings Call Transcript August 29, 2024 9:00 AM ET Company Participants Glenn David - CFO Jack Bendheim - Chairman, President, and CEO Daniel Bendheim - Director and EVP of Corporate Strategy Conference Call Participants Michael Ryskin - Bank of America Navann Ty - BNP Paribas Operator Good morning. My name is Julianne and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation's ...

Phibro Animal Health Corporation Webcast and Conference Call August 29, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2024 Fourth Quarter Ended June 30, 2024 August 29, 2024 Webcast and Conference Call Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and levera ...